Applying New Stem Cell Science to Reboot the Immune System

Magenta Therapeutics (NASDAQ: MGTA) is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

February 21, 2019
Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant

February 7, 2019
Magenta Therapeutics to Present at Guggenheim Healthcare Investor Conference

January 2, 2019
Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019

Read More News

Associated Team Members

Alexis Borisy

Stephen Sherwin, M.D.
Venture Partner